Jump to navigation

News

Top News

  • EVENT Poster presentation at ISSCR Annual Meeting 2017

    Xcell Biosciences is presenting a poster at ISSCR 2017 Annual Meeting in Boston this year! The ISSCR annual meeting brings together stem cell researchers from around the world to share their work, discuss tools and techniques, and advance stem cell science and regenerative medicine.

    Poster:
    Application of Atmospheric Pressure During Culture Promotes Neural Progenitor and Adult Neuronal Cell Differentiation in iPSCs

    When: Poster Session II-EVEN 7-8pm, Thursday, June 15, 2016
    Where: Poster Board #T-2146
    Abstract:
    Induced pluripotent stem cells (iPSCs) can be used for autologous regenerative medicine to treat a multitude of health conditions, including debilitating injuries and genetic diseases. In order for iPSCs to be suitable for clinical use it is critical to optimize re-programming and differentiation conditions to consistently achieve functional and genetic attributes for target cells of interest, and in cell quantities that are therapeutically relevant. Recent studies have highlighted the significance of environmental factors such as oxygen concentration and pressure in stem cell culture; however, none have evaluated the combined effect of these factors for manipulating stem cell state. Previously we have shown increased efficiency in somatic cell reprogramming to iPSCs through cell culture in low oxygen and high pressure. Here we aimed to build on these previous works and demonstrate the relevance of a combination of hypoxia and pressure in directed differentiation in iPSCs using a custom bioreactor technology.

    We have developed a primary cell culture bioreactor, the AVATAR™, to provide tunable control of the microenvironment ex vivo and aimed to use this capability to optimize iPSC culture and directed differentiation. We used AVATAR™-defined settings for oxygen concentration (1-5%) and atmospheric pressure (0-5 PSI) and then assessed the impact of these conditions on stem cell state by evaluating expression of pluripotency-associated genes by RT-qPCR and immunofluorescence staining, whole-transcriptome sequencing, and directed differentiation into all three germ layers. Preliminary data of gene expression analysis indicates that iPSCs cultured in 2-5 PSI exhibit a spontaneous downregulation of pluripotency-related genes and upregulation of genes involved in neural induction. Differentiation studies subsequently showed long term culture with pressure substantially increased neural progenitor cell generation via PAX6 and neural cadherin (CDH2) expression and consequently allowed more efficient differentiation of iPSCs towards neurons and astrocytes. Our findings suggest that physiologically relevant oxygen and pressure are important factors in stem cell fate and can be useful stimuli for controlling and driving differentiation towards neural cell lineages.

    Read more information on the conference at isscr.org/home/annual-meeting/isscr-2017-boston

  • We are hiring for a Field Application Scientist

    Scope
    • Field Application Support Associate/Specialist/Scientist will support the Avatar application areas,
    lead and organize product demonstrations, support sales efforts and provide customer technical
    assistance.
    Duties
    • Work closely with scientists to release new products and protocols
    • Conduct in-house and at customer site wet bench experiments and demonstrations
    • Interpret and troubleshoot results
    • Work closely with the sales and marketing team on introducing the company and product to new
    customers
    • Collaborate effectively with other scientists to help advance the company’s research and business
    goals
    Qualifications
    • M.S. or Ph.D degree in molecular biology, cell biology, biochemistry,
    bioengineering, or biology related discipline with key focus and experience in cell
    culture.
    • Good laboratory skills in molecular biology with 2-4 years of lab experience in cell
    culture, DNA and RNA isolation, basic microscopy, sterile techniques.
    • Good verbal and written communication skills, knowledge of computers (both
    Apple OS and Microsoft Windows platform), and willingness to learn new
    techniques.
    • Good record keeping skills.
    • Previous experience working with and or culturing of human primary cells (immune cells, IPSCs, or
    tumor cells) is a plus
    • Capacity to work in a fast-paced environment coupled with the emerging challenges of a rapidly
    evolving field
    • Highly motivated, independent self-starter
    • Interpersonally savvy and skillful collaborator
    • Resiliency and flexibility around shifting work streams and timeframes
    • Focused and meticulous with good attention to detail
    • Able to communicate effectively both verbally and in writing

    To apply, please send CV and cover letter to careers [at] xcellbio.com
    See full job posting HERE

  • ARTICLE: Illumina Interview with CEO Brian Feth

    March 15, 2017 | Illumina News Center

    Last month, Xcell Biosciences announced closing its $12 million Series A financing. The company will use the funds to launch its commercial platform worldwide, including expanding its U.S. sales force and worldwide commercial reach. Illumina News Center caught up with co-founder and CEO Brian Feth to discuss life after Illumina Accelerator and what’s next for the thriving company.

    Read the full interview here

    Link not loading? Read the PDF here

  • ARTICLE: Feature in Science Magazine

    March 10, 2017 | Science Magazine | Vol. 355, Issue 6329, pp. 1085
    The Avatar System was featured under "New Products" in Science Magazine.

    Read the full article in Science HERE
    See PDF version HERE

  • We are hiring for a Mechanical Engineer

    We are looking for a mid to senior level mechanical engineer to conduct design and manufacturing engineering to support the Avatar instrument. An ideal candidate will have experience designing pressure vessels, temperature control systems, plumbing for gas composition control, and basic electronics. They will also be experienced generating manufacturing documentation to be used by a contract manufacturer. Finally, they should have experience servicing and supporting instruments.

    Responsibilities
    • Design and prototype improvements to the Avatar instrument as well as new product development.
    • Design experiments to verify products meets design and marketing specifications.
    • Create manufacturing documentation and train contract manufacturers.
    • Work with customer facing teams to create troubleshooting, service, and repair documentation.
    • Work with R&D and customer facing teams to troubleshoot customer issues and repair broken equipment.

    Skills, Technical Expertise, and Experience
    • Degree in Mechanical Engineering or another related field. At least 4 years of engineering experience with a Bachelor’s and at least 1 year with a Master’s.
    • Experience designing and developing lab measurement and test equipment.
    • Hands-on experience designing, building, and testing new product prototypes.
    • Can demonstrate proficiency in Solidworks to design parts and create engineering drawings.
    • Proficient oral and written communications skills.
    • Can demonstrate ability to write engineering and manufacturing documentation. Can demonstrate ability to document experimental test reports.

    Personal Characteristics
    • Highly motivated self-starter that is comfortable working independently.
    • Takes a ”hands-on” approach to problem solving.
    • Must be comfortable in an early-stage start-up environment, with a mix of cash, equity, and milestone-based compensation.
    • Please note if you are legally authorized to work in the United States in your application.
    • The role is being actively recruited for; resumes will be reviewed on a rolling basis.

    To apply, please send a CV and cover letter to careers {@ } xcellbio.com
    or apply on our LinkedIn page HERE
    Full job posting HERE

  • PRESS RELEASE: $12M Series A Funding Round

    SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences announced today the company has closed a $12 million Series A private equity financing round. The financing was led by HBM Genomics along with the continued participation of all major existing investors. Xcell Bio will use the funds to launch its commercial platform worldwide, including expanding its US sales force and worldwide commercial reach. Saeid Akhtari, Managing Director of HBM Genomics, will join the Xcell Biosciences Board of Directors.

    See the full article on Business Wire HERE

  • [FILLED] We are hiring a East Coast Sales Accou...

    The East Coast Sales Account Executive will be responsible for building and supporting new and existing accounts for Xcellbio and the entire product family. You will work primarily with research institutions, integrated pharma, and academia business to identify key accounts, establish new business, and build strategic relationship. The position will have total ownership of relationship with designated accounts and drive business results by promoting and selling Xcellbio products.

    To be successful in this role, you will:

     Develop and foster relationships with Key Opinion Leaders and Key Decision Makers at target accounts
     Develop and execute business plans to grow all areas of target markets
     Coordinate solution sales in targeted accounts
     Manage and lead the development and implementation of sales strategies to attain assigned sales objectives for highly strategic accounts
     Aid in planning, organizing, and controlling balanced sales growth, continued account penetration, and customer satisfaction
     Utilize strong product/market knowledge and sales experience to manage complex sales and resolve customer questions and concerns
     Continuously build knowledge of current industry trends, competitive information, and industry/technical knowledge and share with other Xcellbio colleagues
     Retain, extend, and acquire customers through effective identification of opportunities and the creation and implementation of solutions
     Establish and build strong client relationships that allow for growth, profitability and predictability.

    Application: Interested candidates should send a CV and cover letter to careers{at}xcellbio.com

    Xcell Biosciences is a San Francisco-based life science start-up company that has developed an innovative high content
    primary cell culture platform for use in research, drug development, and precision medicine applications. The technology delivers simple, standardized culture of primary cell types from a variety of patient tissues and blood, including expansion of tumor cells and immune cells. This novel platform enables direct disease insights ex vivo, with use in drug development applications ranging from novel cancer biomarker discovery to cell-based immunotherapy lead optimization. This patient-centric company is developing the next generation of the platform as a liquid biopsy tool for cancer screening, diagnosis, and disease monitoring.

Recent News

  • EVENT Poster presentation at ISSCR Annual Meeting 2017

    Xcell Biosciences is presenting a poster at ISSCR 2017 Annual Meeting in Boston this year! The ISSCR annual meeting brings together stem cell researchers from around the world to share their work, discuss tools and techniques, and advance stem cell science and regenerative medicine.

    Poster:
    Application of Atmospheric Pressure During Culture Promotes Neural Progenitor and Adult Neuronal Cell Differentiation in iPSCs

    When: Poster Session II-EVEN 7-8pm, Thursday, June 15, 2016
    Where: Poster Board #T-2146
    Abstract:
    Induced pluripotent stem cells (iPSCs) can be used for autologous regenerative medicine to treat a multitude of health conditions, including debilitating injuries and genetic diseases. In order for iPSCs to be suitable for clinical use it is critical to optimize re-programming and differentiation conditions to consistently achieve functional and genetic attributes for target cells of interest, and in cell quantities that are therapeutically relevant. Recent studies have highlighted the significance of environmental factors such as oxygen concentration and pressure in stem cell culture; however, none have evaluated the combined effect of these factors for manipulating stem cell state. Previously we have shown increased efficiency in somatic cell reprogramming to iPSCs through cell culture in low oxygen and high pressure. Here we aimed to build on these previous works and demonstrate the relevance of a combination of hypoxia and pressure in directed differentiation in iPSCs using a custom bioreactor technology.

    We have developed a primary cell culture bioreactor, the AVATAR™, to provide tunable control of the microenvironment ex vivo and aimed to use this capability to optimize iPSC culture and directed differentiation. We used AVATAR™-defined settings for oxygen concentration (1-5%) and atmospheric pressure (0-5 PSI) and then assessed the impact of these conditions on stem cell state by evaluating expression of pluripotency-associated genes by RT-qPCR and immunofluorescence staining, whole-transcriptome sequencing, and directed differentiation into all three germ layers. Preliminary data of gene expression analysis indicates that iPSCs cultured in 2-5 PSI exhibit a spontaneous downregulation of pluripotency-related genes and upregulation of genes involved in neural induction. Differentiation studies subsequently showed long term culture with pressure substantially increased neural progenitor cell generation via PAX6 and neural cadherin (CDH2) expression and consequently allowed more efficient differentiation of iPSCs towards neurons and astrocytes. Our findings suggest that physiologically relevant oxygen and pressure are important factors in stem cell fate and can be useful stimuli for controlling and driving differentiation towards neural cell lineages.

    Read more information on the conference at isscr.org/home/annual-meeting/isscr-2017-boston

  • We are hiring for a Field Application Scientist

    Scope
    • Field Application Support Associate/Specialist/Scientist will support the Avatar application areas,
    lead and organize product demonstrations, support sales efforts and provide customer technical
    assistance.
    Duties
    • Work closely with scientists to release new products and protocols
    • Conduct in-house and at customer site wet bench experiments and demonstrations
    • Interpret and troubleshoot results
    • Work closely with the sales and marketing team on introducing the company and product to new
    customers
    • Collaborate effectively with other scientists to help advance the company’s research and business
    goals
    Qualifications
    • M.S. or Ph.D degree in molecular biology, cell biology, biochemistry,
    bioengineering, or biology related discipline with key focus and experience in cell
    culture.
    • Good laboratory skills in molecular biology with 2-4 years of lab experience in cell
    culture, DNA and RNA isolation, basic microscopy, sterile techniques.
    • Good verbal and written communication skills, knowledge of computers (both
    Apple OS and Microsoft Windows platform), and willingness to learn new
    techniques.
    • Good record keeping skills.
    • Previous experience working with and or culturing of human primary cells (immune cells, IPSCs, or
    tumor cells) is a plus
    • Capacity to work in a fast-paced environment coupled with the emerging challenges of a rapidly
    evolving field
    • Highly motivated, independent self-starter
    • Interpersonally savvy and skillful collaborator
    • Resiliency and flexibility around shifting work streams and timeframes
    • Focused and meticulous with good attention to detail
    • Able to communicate effectively both verbally and in writing

    To apply, please send CV and cover letter to careers [at] xcellbio.com
    See full job posting HERE

  • ARTICLE: Illumina Interview with CEO Brian Feth

    March 15, 2017 | Illumina News Center

    Last month, Xcell Biosciences announced closing its $12 million Series A financing. The company will use the funds to launch its commercial platform worldwide, including expanding its U.S. sales force and worldwide commercial reach. Illumina News Center caught up with co-founder and CEO Brian Feth to discuss life after Illumina Accelerator and what’s next for the thriving company.

    Read the full interview here

    Link not loading? Read the PDF here

  • ARTICLE: Feature in Science Magazine

    March 10, 2017 | Science Magazine | Vol. 355, Issue 6329, pp. 1085
    The Avatar System was featured under "New Products" in Science Magazine.

    Read the full article in Science HERE
    See PDF version HERE

  • EVENT Visit us at Keystone Symposia: Tumor Metabolism

    Xcell Biosciences is a proud sponsor of Keystone Symposia's "Tumor Metabolism: Mechanisms and Targets" Conference, held this year in Whistler, British Columbia, Canada.

    This conference is on the rapidly moving field of tumor metabolism and its implications in cancer development, progression and therapy. Experts from distinct fields of research will be brought together to present their latest discoveries on tumor metabolism, which is an inherently interdisciplinary field. Defining the diversity of metabolic strategies employed by cancer cells and how the genetic events underlying different types of cancer, as well as the tumor microenvironment, influence these metabolic properties is a major goal of this meeting. In addition, a combination of basic, translational and clinical studies will be presented, with the goal of identifying promising avenues in tumor metabolism that impact our understanding, diagnosis and treatment of cancer. In addition to a stellar line up of invited speakers, short talks and poster presentations will provide opportunities for researchers at all levels to discuss their most current work in this field. This meeting provides an excellent opportunity to share knowledge and methodology in tumor metabolism research in a collegial and social atmosphere.

    Please feel free to stop by Xcell Bioscience's booth at the conference as our scientists will be happy to answer any questions.

    Tumor Metabolism: Mechanisms and Targets
    March 5—9, 2017
    Whistler Conference Centre, Whistler, British Columbia, Canada

    Full meeting program HERE

  • We are hiring for a Mechanical Engineer

    We are looking for a mid to senior level mechanical engineer to conduct design and manufacturing engineering to support the Avatar instrument. An ideal candidate will have experience designing pressure vessels, temperature control systems, plumbing for gas composition control, and basic electronics. They will also be experienced generating manufacturing documentation to be used by a contract manufacturer. Finally, they should have experience servicing and supporting instruments.

    Responsibilities
    • Design and prototype improvements to the Avatar instrument as well as new product development.
    • Design experiments to verify products meets design and marketing specifications.
    • Create manufacturing documentation and train contract manufacturers.
    • Work with customer facing teams to create troubleshooting, service, and repair documentation.
    • Work with R&D and customer facing teams to troubleshoot customer issues and repair broken equipment.

    Skills, Technical Expertise, and Experience
    • Degree in Mechanical Engineering or another related field. At least 4 years of engineering experience with a Bachelor’s and at least 1 year with a Master’s.
    • Experience designing and developing lab measurement and test equipment.
    • Hands-on experience designing, building, and testing new product prototypes.
    • Can demonstrate proficiency in Solidworks to design parts and create engineering drawings.
    • Proficient oral and written communications skills.
    • Can demonstrate ability to write engineering and manufacturing documentation. Can demonstrate ability to document experimental test reports.

    Personal Characteristics
    • Highly motivated self-starter that is comfortable working independently.
    • Takes a ”hands-on” approach to problem solving.
    • Must be comfortable in an early-stage start-up environment, with a mix of cash, equity, and milestone-based compensation.
    • Please note if you are legally authorized to work in the United States in your application.
    • The role is being actively recruited for; resumes will be reviewed on a rolling basis.

    To apply, please send a CV and cover letter to careers {@ } xcellbio.com
    or apply on our LinkedIn page HERE
    Full job posting HERE

  • PRESS RELEASE: $12M Series A Funding Round

    SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences announced today the company has closed a $12 million Series A private equity financing round. The financing was led by HBM Genomics along with the continued participation of all major existing investors. Xcell Bio will use the funds to launch its commercial platform worldwide, including expanding its US sales force and worldwide commercial reach. Saeid Akhtari, Managing Director of HBM Genomics, will join the Xcell Biosciences Board of Directors.

    See the full article on Business Wire HERE

  • [FILLED] We are hiring a East Coast Sales Accou...

    The East Coast Sales Account Executive will be responsible for building and supporting new and existing accounts for Xcellbio and the entire product family. You will work primarily with research institutions, integrated pharma, and academia business to identify key accounts, establish new business, and build strategic relationship. The position will have total ownership of relationship with designated accounts and drive business results by promoting and selling Xcellbio products.

    To be successful in this role, you will:

     Develop and foster relationships with Key Opinion Leaders and Key Decision Makers at target accounts
     Develop and execute business plans to grow all areas of target markets
     Coordinate solution sales in targeted accounts
     Manage and lead the development and implementation of sales strategies to attain assigned sales objectives for highly strategic accounts
     Aid in planning, organizing, and controlling balanced sales growth, continued account penetration, and customer satisfaction
     Utilize strong product/market knowledge and sales experience to manage complex sales and resolve customer questions and concerns
     Continuously build knowledge of current industry trends, competitive information, and industry/technical knowledge and share with other Xcellbio colleagues
     Retain, extend, and acquire customers through effective identification of opportunities and the creation and implementation of solutions
     Establish and build strong client relationships that allow for growth, profitability and predictability.

    Application: Interested candidates should send a CV and cover letter to careers{at}xcellbio.com

    Xcell Biosciences is a San Francisco-based life science start-up company that has developed an innovative high content
    primary cell culture platform for use in research, drug development, and precision medicine applications. The technology delivers simple, standardized culture of primary cell types from a variety of patient tissues and blood, including expansion of tumor cells and immune cells. This novel platform enables direct disease insights ex vivo, with use in drug development applications ranging from novel cancer biomarker discovery to cell-based immunotherapy lead optimization. This patient-centric company is developing the next generation of the platform as a liquid biopsy tool for cancer screening, diagnosis, and disease monitoring.

  • [FILLED] We are hiring a West Coast Sales Accou...

    The West Coast Sales Account Executive will be responsible for building and supporting new and existing accounts for Xcellbio and the entire product family. You will work primarily with research institutions, integrated pharma, and academia business to identify key accounts, establish new business, and build strategic relationship. The position will have total ownership of relationship with designated accounts and drive business results by promoting and selling Xcellbio products.

    To be successful in this role, you will:

     Develop and foster relationships with Key Opinion Leaders and Key Decision Makers at target accounts
     Develop and execute business plans to grow all areas of target markets
     Coordinate solution sales in targeted accounts
     Manage and lead the development and implementation of sales strategies to attain assigned sales objectives for highly strategic accounts
     Aid in planning, organizing, and controlling balanced sales growth, continued account penetration, and customer satisfaction
     Utilize strong product/market knowledge and sales experience to manage complex sales and resolve customer questions and concerns
     Continuously build knowledge of current industry trends, competitive information, and industry/technical knowledge and share with other Xcellbio colleagues
     Retain, extend, and acquire customers through effective identification of opportunities and the creation and implementation of solutions
     Establish and build strong client relationships that allow for growth, profitability and predictability.

    Application: Interested candidates should send a CV and cover letter to careers{at}xcellbio.com

    Xcell Biosciences is a San Francisco-based life science start-up company that has developed an innovative high content
    primary cell culture platform for use in research, drug development, and precision medicine applications. The technology delivers simple, standardized culture of primary cell types from a variety of patient tissues and blood, including expansion of tumor cells and immune cells. This novel platform enables direct disease insights ex vivo, with use in drug development applications ranging from novel cancer biomarker discovery to cell-based immunotherapy lead optimization. This patient-centric company is developing the next generation of the platform as a liquid biopsy tool for cancer screening, diagnosis, and disease monitoring.

  • ARTICLE: Feature in PM360 2016 Innovator's Issue

    December 21st, 2016 | PM360 Staff
    Xcellbio's Avatar System is featured in PM360’s Innovations Issue.

    PM360’s Innovations Issue, established five years ago, serves as a comprehensive guide to readers on the year’s most cutting-edge products.

    Read more on how the Avatar System and other innovations on PM360: HERE

    PDF Version

  • EVENT Visit us at American Society of Cell Biology '16

    We will have two poster presentations and vendor presence (Booth 816) at American Society of Cell Biology (ASCB 2016), December 4-6, 2016!

    Swing by and see the newest model of Avatar and ask our friendly scientists questions on your cell culturing needs. Be amazed by some magic and great giveaways, including a raffle for a Mini iPad when you drop by the booth!

    At our poster talks, learn about generating iPSCs from adult somatic cells by optimizing pressure and oxygen, and using pressure to induce differentiation of iPSCs into neural progenitor cells! Discuss how hypoxia and pressure activate AR variants in prostate cancer cells, induce epithelial mesenchymal transition (EMT), and contribute to development of castration-resistant metastatic prostate cancer. More information on the posters below.

    POSTER 1: Hypoxia and pressure induce prostate androgen receptor [AR] variant expression and contribute to development of castration-resistant metastatic prostate cancer
    Sunday, December 4, 1:30-3pm
    Board Number: B559
    ASCB Learning Center, Exhibit Halls A-C, Moscone South
    San Francisco, CA

    POSTER 2: Tuning the stem cell microenvironment: oxygen and pressure are key players in iPSC generation and differentiation
    Monday, December 5, 1:30-3pm
    Board Number: B240 
    ASCB Learning Center, Exhibit Halls A-C, Moscone South
    San Francisco, CA

  • EVENT 2016 AIChE Annual Meeting

    Platform presentation at 2016 American Institute of Chemical Engineers (AIChE) Annual Meeting, Nov 13-18, 2016, San Francisco

  • ARTICLE: Incubator Architecture in Biocompare

    November 8, 2016 - Josh P. Roberts

    "As people move from culturing hardy cell lines to culturing primary cells, stem cells and even 3D cultures, it’s increasingly important to be able to control O2-levels, as well, to better mimic hypoxia in an in vivo environment. Many vendors now offer CO2 incubators in which hypoxic environments are created by introducing nitrogen gas. Eppendorf, for example, offers two options: 0.1% to 19%, or 1% to 19%, O2 control.

    There are also incubators that create hyperoxic conditions. “They’re less popular—a bit more of a niche application,” says Bates. “Sometimes people use them to study retinal cells or lung conditions or [to look] at reactive O2 species.”

    Xcell Biosciences' diminutive (3.7-liter) Avatar system takes atmospheric control one step further: “We’re able to mimic the range of pressure conditions found all the way from the circulation to the bone marrow to the fluids found within the brain,” notes chief scientific officer James Lim."

    Read the full article: PDF Version

  • ARTICLE: Interview with the Innovators in PMO

    October 18, 2016 | Personalized Medicine in Oncology
    A New Approach to Cell Culturing
    An Interview with James Lim, PhD, of Xcell Biosciences

    The drug discovery process has long been characterized by very low success rates in moving compounds from early-stage studies to clinically proven therapeutics. A confounding factor in the process is the inability to conduct high-throughput screening in an environment that truly mirrors human physiology. These early-stage tests are typically performed on cell lines that have been maintained and expanded over many years under conditions that rarely reflect in vivo settings. The cell culture incubators housing cell lines cannot fully reproduce the native conditions of the cells, and even small environmental changes can significantly alter the cells’ gene and protein expression signatures that contribute to changes in drug sensitivity.

    To address these issues, Xcell Biosciences created the Avatar system to help drug discovery researchers generate more physiologically relevant data to identify and advance the best candidates to clinical trials...

    Read the full interview on Personal Medicine in Oncology

    PDF Version

  • EVENT Poster at 2016 American Society of Human Genetics

    Bryan Downie from Xcellbio will be present at 2016 American Society of Human Genetics Annual Meeting in Vancouver, B.C., from October 18-October 22, 2016 to talk on his poster, "Identification of prostate cancer driver mutations and transcriptomic profiling from cultured circulating tumor cells."

    The ASHG Annual Meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. This year’s meeting is expected to attract over 6,500 scientific attendees, plus over 200 exhibiting companies.

    ASHG members and leading scientists from around the world will present their research findings at invited, platform, and poster sessions. The meeting also offers an Exhibit Hall featuring state-of-the-art medical and laboratory equipment, products, services, and computer software designed to enhance human genetics research, teaching, and consultation.

    Register HERE
    Schedule of events

  • EVENT Poster at Cell Symposia: Tech:Bio:Data Science '16

    Bryan Downie from Xcellbio will present on "Identification of prostate cancer driver mutations and transcriptomic profiling from cultured circulating tumor cells.” and “Characterization of the effects of hypoxia and atmospheric pressure on the expression of immunotherapeutic targets and drug susceptibility” at Cell Symposia: Technology. Biology. Data Science

    The meeting will be held from October 9–11, 2016 at The Claremont Hotel Club and Spa in Berkeley, California. Fostering collaboration and cross-disciplinary discussions will be a key theme, so in addition to short scientific talks, attendees will be treated to on-stage interviews, panel discussions, and plenty of in-person social and networking opportunities with each other and the invited speakers. Topics ranging from systems and synthetic biology, digital healthcare, cancer, genomics, immunology, biological engineering, microbiology, and cell biology will be covered.

    More information can be found HERE

  • ARTICLE: Cell Based Assays 2016 in Biocompare

    "Imaging cytometers, high-content analysis workstations and microscopes fitted with environmental chambers all enable live imaging in a constant environment without perturbing the cells over time. Yet when leading up to and running long-term assays—even endpoint assays—giving the cells an environment that more closely mimics the in vivo environment may enable a more physiological assessment of how cells would, say, proliferate in the stem cell niche under the test conditions, points out James Lim, chief scientific officer at Xcell Biosciences. Xcell’s desktop-printer-sized Avatar™ System allows for precise control of both oxygen and pressure. “We’re able to mimic the range of pressure conditions found all the way from the circulation to the bone marrow to the fluid pressures found within the brain,” he says."

    Read more on some methods that are used to monitor and characterize cells : Cell Based Assays

    PDF Version

  • PRESS RELEASE International Distributors Announced

    San Francisco – October 4, 2016 – Xcell Biosciences, Inc., today announced it has signed agreements with two international distributors and made a number of international sales for its Avatar™ system.

    Cambridge Bioscience is now the exclusive United Kingdom distributor, with multiple system sales to date to Cancer Research UK, where the Avatar system will be used by the Carlos Caldas lab in their functional genomics studies of breast cancer.

    In Japan, BioStream has been selected as a distributor for the full line of Xcell products. Several system sales have already been booked for Kyushu University, where the Avatar system will be used by Koichi Akashi’s lab, which specializes in studying immunology, hematology and cancer stem cells.

    Read the FULL PRESS RELEASE

  • EVENT Poster presentation at Cell Symposia iPSC 2016

    Zack Pappalardo from Xcellbio presents a poster on "Tuning the stem cell microenvironment: oxygen and pressure are key players in iPSC generation and differentiation" Tuesday, September 27, 2016, 13:15-14:45 at Cell Symposia: 10 Years of iPSCs. The symposium will be focused on iPSC research and applications. Drop by to chat with the Xcellbio team as well as to see symposium speakers such as Shinya Yamanaka, George Daley, Christine Mummery, Lorenz Studer, and Deepak Srivastava, and Bioethicist Hank Greely speak.

    Poster abstract: HERE
    View Poster
    More information on registering for the conference HERE

  • ARTICLE: Immuno-profiling Feature in GenomeWeb

    Sep 22, 2016 | a GenomeWeb staff reporter
    NEW YORK (GenomeWeb) – Xcell Biosciences announced today that it has partnered with the University of California, San Francisco to conduct pilot studies evaluating the company's Avatar cell culture system and analytics platform in the immunoprofiling of cancer patients.

    Read full feature in GenomeWeb: HERE

    PDF Version

  • PRESS RELEASE: Collaborations in Urologic Cancers

    San Francisco – September 22, 2016 – Xcell Biosciences Initiates New Collaborations with UCSF Researchers Studying Effectiveness of Immunotherapy in Urologic Cancers.

    Studies Assess the Ability to Predict Prognosis and Response to Therapies by Immunoprofiling of Patients’ Blood, Cultured and Conditioned with Xcell’s Unique Avatar System

    Xcell Biosciences, Inc., announced today that it has extended its collaborative work with the University of California, San Francisco (UCSF) to include working with three principal investigators on pilot studies using Xcell’s Avatar cell culture system and proprietary analytics platform. The work will determine if large scale RNA profiling from peripheral blood and other patient-derived sample sources cultured in the Avatar System and correlated to clinical outcomes can predict a patient’s response to first or second line treatments in prostate, bladder and kidney cancers.

    Read the full press release HERE

  • ARTICLE: 2016 Instrument Business Outlook Award

    Congratulations to Xcell Biosciences for winning the 2016 Instrument Business Outlook (IBO) Silver Award for excellence in laboratory product design for the Avatar. Each year, IBO recognizes innovative and functional industrial design of analytical
    instruments, laboratory equipment and portable instrumentation.

    'The winner of the 2016 Silver Design Award for lab equipment is Xcell Biosciences’ Avatar System for controlling the microenvironments of cells, including hydrostatic pressure, oxygen, temperature, humidity and carbon dioxide. Consequently, it expands capabilities to culture samples. The novel design visually signals the system’s new approach to cell growth and maintenance. The Avatar System offers a fresh update of standard incubators, utilizing a playful circular door configuration, glossy black finish, and bold shapes and color contrasts. The circular door slides up, and large digital displays provide a prominent read out of environmental conditions. Designed by Juggernaut Design, the Avatar measures 13.5 x 13.1 x 12 in (34.3 x 33.3 x 30.5 cm) and weighs 63lb (28.6 kg). It has a chamber capacity of 3.7 L.

    According to Martin Pieprzyk, executive vice president at Xcell, “The priorities for the design were ease of use [and a] small stackable design, which enabled users to place the instruments into labs with limited space and cell culture hoods. We also focused on user friendly setup and installation, as well as a clean and modern design.” '

    Read more HERE

  • ARTICLE in C&I: Swimming with cells

    "Take a fish out of water and it will die, so the old adage goes. And if it doesn’t die immediately, then it will suffer acute metabolic and respiratory changes that completely distort its biology."

    Chemistry & Industry Magazine interviews Xcellbio co-founders Brian Feth and James Lim on the science and concept behind the Avatar platform as well as the founding of Xcell Biosciences.

    Read the full article on SCI

    PDF Version

  • ARTICLE: Avatar Features in Science

    The Avatar system is featured in Science (05 Aug 2016: Vol. 353, Issue 6299, pp. 610) under their "New Product" section for "[providing] a new platform for culturing and propagating tumor samples, circulating tumor cells from liquid biopsies, stem cells, and primary samples. In addition to enabling the culturing of difficult samples such as tumor biopsies and primary samples, the system overcomes the limitations of traditional cell cultures to generate results that exhibit the phenotypic, genomic, and proteomic characteristics of the native sample."

    Read the full article on Science HERE

  • ARTICLE: Feature in American Laboratory

    Delve into how advancement in cancer research starts on better cell culture practice in Cell Culture Advances Yield More Reliable Data for Cancer Research. Featured in American Laboratory and written by Xcellbio's own CSO, James Lim, the article explores how "reliable, relevant data from cultured cells will lead to a better understanding of the biological mechanisms involved in cancer formation and metastasis and creative new approaches for treating patients."

    Read the full article on American Laboratory

  • ARTICLE: Feature in Drug Discovery World

    Dr. James Lim of Xcell Biosciences and Dr. Fred Aswad of Bayer co-author an article in Drug Discovery World titled "EX VIVO versus IN VIVO - the challenge of generating meaningful results with traditional cell culture".

    This article discusses current attempts to make results from cell culture systems more biologically relevant which, in turn, could lead to an innovative era of transformation in how we use cells throughout the biomedical community.

    Read the full article on Drug Discovery News
    PDF version HERE

  • EVENT AACR Engineering and Physical Sciences in Oncology

    Luke Cassereau, Xcellbio scientist, will be doing a poster presentation on "Systematic modulation of the physical microenvironment for characterization of cancer cell lines and primary tissue" at the AACR Engineering and Physical Sciences in Oncology, June 25-28, 2016, Boston

    Session Date and Time: Poster Session A on Sunday, June 26, 2016 from 1:00 pm - 3:30 pm
    Session Location: Westin Boston Waterfront, Galleria Hall
    Poster Board Number: A42

    For more information on AACR 2016 : http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=70#.V184_pMrLfZ

  • ARTICLE: Bayer's CoLaborator: A Startup Hub...

    Scrips Intelligence writes an article on " Bayer's CoLaborator: A Startup Hub In San Francisco's Biotech Cluster" on Bayer's CoLaborator "developing relationships [and] nurturing partnerships" with biotech startup companies, such as Xcellbio "...has developed proprietary cell culture technology known as Avatar and a product called the Avatar Bioreactor, which is designed to screen drug compounds and diagnose diseases, among other research tasks; Bayer bought one of Xcell's first Avatar machines..." Read more at HERE

  • EVENT ISSCR 2016 Annual Meeting

    Poster presentation by Luke Cassereau on Creating a Tunable Stem Cell: Modulation of Oxygen and Atmospheric Pressure During Culture Alters Signaling Pathways Poster #T3004. Thursday, June 23rd at 6pm PST.
    Swing by if you have any questions!

    Xcell Biosciences will also have vendor info displayed at Illumina's booth #1247 at the International Society of Stem Cell Research 2016 Annual Meeting, June 22-25, San Francisco
    Program Schedule: http://bit.ly/28QYpbV

  • EVENT Innovation Panel at 17th BIC System-wide Symposium

    Xcell Bioscience scientist, Luke Cassereau, who earned his PhD from from the UC Berkeley-UCSF joint graduate group in bioengineering, has been invited to be a member of the Innovators Panel at this year's 17th Bioengineering Institute of California (BIC) System-wide Symposium. He will be speaking, along with other industry innovators, on his experience as an "innovator" in science. Xcell Biosciences will also be present as a table-top vendor throughout the symposium from 6/13-6/15 for any questions and information on what we do. Watch his presentation HERE

    The 17th Annual University of California (UC) Systemwide Bioengineering Symposium brings together faculty and student researchers from each of the ten UC campuses as well as top industry innovators to inspire collaboration. This event, co-sponsored by the Bioengineering Institute of California (BIC), promises a wide variety of networking and presentation opportunities, from the traditional plenary talks and panel discussions to a research speed date and short general audience talks in the evenings.

    For more information: pharm.ucsf.edu/bic

    Date: Tuesday, June 14, 2016, from 5 pm to 6 pm.
    Place: Genentech Hall Byers Auditorium
    600 16th St.
    San Francisco, CA 94158-2517

  • PRESS RELEASE Xcellbio in 2016 Red Herring Top 100

    Newport Beach, Calif — Red Herring today announced its Top 100 North America award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries.

    Red Herring Top 100 America enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the US and Canada. Since 1996, Red Herring has kept tabs on these up-and-comers. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, Palo Alto Networks and eBay would change the way we live and work.

    “In 2016, selecting the top achievers was extremely difficult,” said Alex Vieux, publisher and CEO of Red Herring. “The variety, depth, disruption and traction we saw from the early stage companies to those with significant scale made it one of the toughest vintages to judge. The North America winners are representative of the amazing ecosystem that never ceases to astound, with new and experienced entrepreneurs continuing to push the barriers of innovation. As one of the winners, Xcell Biosciences should be proud of its accomplishment under such strong competition.”

    Red Herring’s editorial staff evaluated companies on both quantitative and qualitative criteria, such as financial performance, technological innovation and intellectual property, DNA of the founders, business model, customer footprint and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in North America.

    Read full press release on Xcell Biosciences Selected as a 2016 Red Herring Top 100 North America Winner

  • PRESS RELEASE Xcellbio Presents Data at ISSCR 2016

    Press Release Summary:
    Xcell Biosciences will co-present "Creating a Tunable Stem Cell: Modulation of Oxygen and Atmospheric Pressure During Culture Alters Signaling Pathways Governing Stem Cell Maintenance and Differentiation" at the upcoming International Society for Stem Cell Research (ISSCR) annual meeting alongside Illumina, Inc. about its Avatar cell incubation system.

    Read the full press release on HERE

  • EVENT Panel Talk on Next-Gen Seq at UC Berkeley

    Chat with our own Rebecca Rutherford, Director of Product Development at Xcell Biosciences, along with other genomics entrepreneurs on lessons learned from a startup point of view Thursday, June 9, 2016. Open to the public at UC Berkeley. This is part of a full-day event hosted by Illumina and QB3 focused on common applications (RNAseq, MethylSeq) and novel library preparation and sequencing approaches (Ribosomal Profiling, DropSeq, Single-Cell Sequencing). The day starts at 8am and ends at 5pm with our panel talk at 1:30 PM - 2:30 PM during the Breakout Session.

    Full agenda and registration:
    http://eventregistration.illumina.com/events/illumina-next-generation-sequencing-seminar-at-uc-berkeley/event-summary-978a906dd06f4b2f8352292e194b2279.aspx?ct=91c939af-6842-4aa6-a698-a8e6464864b0&RefID=Berkeley%20-%20ISR

    Where: Conference Hall at Stanley Hall 105, Berkeley, California, 94720-3220, USA. Get Directions here: Map

  • CambridgeBio named as exclusive UK distributor

    Xcellbio today announced that it has named CambridgeBio as the exclusive UK distributor (http://www.bioscience.co.uk/). The two companies will work closely on commercializing the Avatar platform in the UK and will leverage each other expertise in cellular assays and molecular biology.

  • EVENT AACR 2016 Annual Meeting

    Poster presentation at AACR 2016 Annual Meeting, April 16-20, New Orleans

  • EVENT Visit us at AACR 2016 in New Orleans

    Come visit us at the 2016 AACR conference in New Orleans, we will be presenting poster number 5122 on Wednesday Apr 20, 2016 8:00 AM - 12:00 PM in the Halls G-J, Poster Section 31. titled: Characterization of the effects of hypoxia and hydrostatic pressure on the expression of immunotherapeutic targets on cell lines used for translational research

  • ARTICLE: Feature in GenomeWeb

    Mar 23, 2016 NEW YORK (GenomeWeb) - XCell Biosciences Aims to Improve CTC Analysis, Biomarker Discovery With New Cell Culture Platform

    XCell Biosciences, a four-year-old startup firm and graduate of Illumina's business accelerator program, recently unveiled its novel platform for culturing and propagating a variety of cell types in an in vivo-like environment to yield more accurate
    and relevant results from downstream molecular analyses

    Read the full Genome Web article: HERE

  • ARTICLE Avatar is featured in Diagnostic World

    Diagnostic World writes an article on "Xcell's New Incubator Promises Lifelike Conditions for Tests on Primary Cells".

    March 14, 2016 | Last week, at the Molecular Medicine Tri Conference in San Francisco, Calif., Xcell Biosciences announced the commercial launch of the Avatar System, a cell incubator designed to mimic real-life microenvironments inside the human body. The platform takes aim at the problem of preserving primary tissue—cell samples collected directly from patients—for long enough to perform experimental or clinical tests, without distorting those cells’ physiology and genetic activity...

    Read More at Diagnostic World HERE

  • EVENT Molecular Medicine Tri-Con 2016

    Vendor launch as well as a panel and poster presentation at Molecular Medicine Tri-Con 2016, March 6-11, 2016, San Francisco

  • PRESS RELEASE: Next Gen Avatar at 2016 TriCon

    Xcell Biosciences to Introduce Next Generation System for Cell-based Assays at the 2016 Molecular Medicine Tri-Conference

    SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences, Inc., announced today that the company will unveil its Avatar system, a revolutionary new platform for culturing and propagating tumor samples, circulating tumor cells (CTCs) from liquid biopsies, stem cells and primary samples, at the Molecular Medicine Tri-Conference taking place March 6-11 in San Francisco.

    Link to Full Press Release

  • Xcell presents Liquid Biopsy work at PMWC 2016
  • EVENT Personalized Medicine World Conference 2016

    Platform presentation at the 10th Annual Personalized Medicine World Conference, January 24-27, 2016, Mountain View

  • EVENT 2016 Genitourinary Cancers Symposium

    Poster presentation at the 2016 Genitourinary Cancers Symposium: Patient-Centric Care- Translating Research to Results, January 7-9, 2016, San Francisco, CA, (Poster Presentation)

  • EVENT AACR Conference on Tumor Microenvironment

    Poster presentation at AACR The Function of the Tumor Microenvironment in Cancer Progression, Jan 7-10, 2016, San Diego

  • [FILLED] We are hiring an NGS Scientist

    Xcell Biosciences is a San Francisco-based life science start-up company that has developed an innovative
    high-content primary cell culture platform for use in research, drug development, and precision medicine
    applications. The technology delivers simple, standardized culture of primary cell types from a variety of
    patient tissues and blood, including expansion of tumor cells and immune cells. This novel platform enables
    direct disease insights ex vivo, with use in drug development applications ranging from novel cancer biomarker
    discovery to cell-based immunotherapy lead optimization. This patient-centric company is developing the next
    generation of the platform as a liquid biopsy tools for cancer screening, diagnosis, and disease monitoring.
    Xcell Biosciences seeks a molecular biology focused research / applications scientist with experience in next-
    generation sequencing (NGS) preparation techniques to support development of novel liquid biopsy-based
    clinical diagnostics products for human tissue.

    Objectives
     To accelerate research and product development in a clinically-focused, rapidly growing
    biotechnology company

    Responsibilities 
    Leads and performs experiments using a variety of molecular biology techniques including Illumina NGS workflows

     Work collaboratively with renowned investigators at research institutions, industry, and clinical laboratories in the US and the EU

     Guides, trains, and manages a supporting team of research associates

     Communicates results of research in both written and oral form to company staff,

    collaborators, and at scientific meetings

     Writes and publishes manuscripts and patents aligned with research priorities

     Performs scientific literature searches and maintains complete referencing

    Typical activities
     DNA/RNA extractions, qPCR/digital PCR, construction of Illumina NGS libraries

    Skills/technical expertise

     Optimize extraction protocols for downstream next-generation sequencing efforts

     Process samples on Illumina NGS equipment and assist with routine maintenance of

    instruments

     Doctorate degree in molecular biology, genetics, cellular biology or other health

    sciences field

     Requires 5 years of experience in independent research in a related field, preferably in

    cancer biology or immuno-oncology

     Demonstrated use of NGS technology and knowledge of NGS analysis tools, particularly

    as related to human health (e.g., whole genome, whole exome, cancer panels, immune

    repertoire sequencing, etc.)

     Hands-on experience with library construction for Illumina sequencing platforms

     Ability to troubleshoot issues with sample preparation and/or sequencing results

     Highly motivated self-starter who can prioritize and “take ownership” of tasks

     Comfortable solving problems independently

     Must be comfortable in a seed-stage start-up environment, and with a mix of cash,

    equity, milestone-based compensation

     Please note if you are legally authorized to work in the United States in your application

  • Xcell nominated “Most Intriguing Company” by QB3
  • Xcell presents data at the GU Summit
  • EVENT 3rd Annual Summit on Genitourinary Malignancies

    Platform and poster presentation at Oncology Meeting Innovations (OMI) 3rd Annual Summit on Genitourinary Malignancies, Including Prostate, Kidney, and Bladder Cancer. October 22-25, Banff Springs, Canada

  • Xcell graduates from the Illumina Accelerator

    Xcellbio is one of the first companies to graduate from the Illumia Accelerator

    Read full Illumina Release

  • EVENT AACR 2015 Annual Meeting

    Poster presentation at American Association Cancer Research (AACR) 2015 Annual Meeting, April 18-22, 2015, Philadelphia

  • [FILLED] We are hiring a Research Scientist

    Xcell Biosciences, Inc. is on the forefront of precision research and medicine through its development of a
    proprietary method for capturing and culturing primary cancer cells and stem cells directly from patient
    blood. The technology combines proprietary cell-binding substrates, culture media, and a specialized growth
    chamber as a new research, drug discovery, and diagnostics platform. Xcell is seeking a (Senior) Research
    Scientist in our research laboratory to support development of cell culture products for human tissue.
    Objectives
     To accelerate research and product development in a clinically-focused, rapidly growing
    biotechnology company

    Responsibilities
     Leads and performs experiments related to technology development and validation

     Works scientific collaborators within/outside of the company

     Guides, trains, and manages a supporting team of research associates

     Communicates results of laboratory research in both written and oral form to company

    staff, collaborators, and at scientific meetings

     Writes and publishes manuscripts and patents aligned with research priorities

     Performs scientific literature searches and maintains complete referencing

     Identifies and writes grants for external funding for research

    Typical activities
     Tissue sample handling: primary tumors, needle biopsies/aspirates, whole blood

    Skills/technical experience

     Maintenance of established primary cells and cell lines

     Material and process improvement and optimization for product development

     Doctorate degree in a related Health Science, such as Cancer Stem Cell Biology,

    Embryology, Oncology, Stem Cell Biology, and clinically-trained Cell Biologists

     Requires 5 years of experience in independent research in a related field, with a

    minimum of three years post-graduate research experience in a related field

     Experience with molecular and cell-based protocols for primary human cell culture,

    including isolation, culture, expansion, and characterization in vitro

     Practical understanding of next-gen sequencing strategies and other genetic and

    proteomic characterization methods

     Strong written and oral communication

     Critical thinking and ability to challenge dogmas in the field

     Applicants with clinical certifications (e.g. phlebotomy) should note in application

     Applicants with light microscopy experience should note in application

     Applicants with applicable experience in a start-up company are given priority

     Assertive and highly motivated; energetic driver; self-starter

     Data-driven, problem solver

     Must be comfortable in a high-risk, fast-paced seed-stage start-up environment

     Must be comfortable with a mix of cash, equity, milestone-based compensation

     Please note if you are legally authorized to work in the United States in your application

    To apply, please send a CV and cover letter to careers@xcellbio.com

  • Xcell signs a master research agreement with UCSF
  • EVENT Bayer LifeScience Workshop 2015

    Platform presentation on "Blood-based Biomarkers for Personalized Therapy" at Bayer LifeScience Workshop, Berlin (January 26-27, 2015)